A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract Extraction
← catalyst calendarSponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
335actual
Sites
62
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-29 | actual | When the study began enrolling |
| Primary completion | 2025-05-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-21 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cataract
Intervention
- Device: enVista Aspire EA or Aspire Toric ETA IOLs
Primary outcomes
what the primary-completion date above is the date OFMean binocular best-corrected distance visual acuity (BCDVA) at Postoperative Visit 1
measured Assessed at Postop visit 1 (Day 14 to 42 days after second eye IOL implantation)
Percentage of subjects with binocular BCDVA of 20/40 or better at Postoperative Visit 1
measured Assessed at Postop visit 1 (Day 14 to 42 days after second eye IOL implantation)
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed